WallStreetZenWallStreetZen

NASDAQ: HUMA
Humacyte Inc Stock Forecast, Predictions & Price Target

Analyst price target for HUMA

Based on 4 analysts offering 12 month price targets for Humacyte Inc.
Min Forecast
$4.00-36.81%
Avg Forecast
$8.00+26.38%
Max Forecast
$15.00+136.97%

Should I buy or sell HUMA stock?

Based on 4 analysts offering ratings for Humacyte Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HUMA stock forecasts and price targets.

HUMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-13
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-03-26
lockedlocked$00.00+00.00%2023-12-11

1 of 1

Forecast return on equity

Is HUMA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.27%

Forecast return on assets

Is HUMA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

HUMA revenue forecast

What is HUMA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$1.7M
Avg 2 year Forecast
$19.6M
Avg 3 year Forecast
$79.2M

HUMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HUMA$6.33$8.00+26.38%Strong Buy
DNTH$25.63$42.40+65.43%Strong Buy
MESO$7.35N/AN/A
WVE$6.26$13.17+110.34%Strong Buy
ALXO$14.21$18.25+28.43%Strong Buy

Humacyte Stock Forecast FAQ

Is Humacyte Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.

Out of 4 analysts, 2 (50%) are recommending HUMA as a Strong Buy, 1 (25%) are recommending HUMA as a Buy, 1 (25%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.

If you're new to stock investing, here's how to buy Humacyte stock.

What is HUMA's revenue growth forecast for 2024-2026?

(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Humacyte's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast HUMA's revenue for 2024 to be $198,870,870, with the lowest HUMA revenue forecast at $107,175,918, and the highest HUMA revenue forecast at $290,565,821. On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $2,329,885,366, with the lowest HUMA revenue forecast at $1,492,126,943, and the highest HUMA revenue forecast at $3,167,643,790.

In 2026, HUMA is forecast to generate $9,435,053,288 in revenue, with the lowest revenue forecast at $8,752,699,946 and the highest revenue forecast at $10,117,406,631.

What is HUMA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: HUMA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is HUMA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $8.00, with the highest HUMA stock price forecast at $15.00 and the lowest HUMA stock price forecast at $4.00.

On average, Wall Street analysts predict that Humacyte's share price could reach $8.00 by May 13, 2025. The average Humacyte stock price prediction forecasts a potential upside of 26.38% from the current HUMA share price of $6.33.

What is HUMA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: HUMA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.